<!doctype html>
<html class="no-js" lang="en">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-55424252-12"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-55424252-12');
    </script>
    <meta charset="utf-8">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <title>RaQualia Pharma Pipeline [4579] - Ariafloat Stock</title>
    <meta name="description" content="RaQualia Pharma Pipeline [4579]">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="icon" type="image/png" href="../../img/boundcat-icon.png">
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/css/bootstrap.min.css" integrity="sha384-PsH8R72JQ3SOdhVi3uxftmaW6Vc51MKb0q5P2rRUpPvrszuE4W1povHYgTpBfshb" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/7.0.0/normalize.min.css">
    <link rel="stylesheet" href="../../css/main.css">
    <link rel="stylesheet" href="../css/raqualia.css">
    <!-- Google AdSense -->
    <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
    <script>
      (adsbygoogle = window.adsbygoogle || []).push({
        google_ad_client: "ca-pub-6825342955400774",
        enable_page_level_ads: true
      });
    </script>
    <!-- Google AdSense  -->
  </head>
  <body id="top">
    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
      <div class="container">
        <a class="navbar-brand" href="http://stock.ariafloat.com/">Ariafloat Stock</a>
        <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
        <div class="collapse navbar-collapse" id="navbarNav">
          <ul class="navbar-nav ml-md-auto">
            <li class="nav-item">
              <a class="nav-link" href="http://stock.ariafloat.com/raqualia/">Japanese</a>
            </li>
            <li class="nav-item">
              <a class="nav-link" href="http://stock.ariafloat.com/raqualia/en/">Top</a>
            </li>
          </ul>
        </div>
      </div>
    </nav>    
    <main role="main" style="text-align: center;">
      <h1 style="text-align: center;">RaQualia Pharma [4579] </h1>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem;">
        <div class="container">
          <h2 style="font-size: 1.7em"><a href="http://stock.ariafloat.com/raqualia/news/" style="text-decoration: underline;">NEWS</a></h2>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem;">
        <div class="container">
          <h2 style="font-size: 1.7em">RaQualia Pharma Research Report</h2>
          <ul style=" max-width: 350px; margin: 0 auto; text-align: left;">
            <li><a href="http://www.raqualia.co.jp/rq-cms/wp-content/uploads/raqualia20180416.pdf" target="_blank" rel="nofollow">FISCO Report [4/16, 2018]</a></li>
            <li><a href="http://search.sbisec.co.jp/v2/popwin/info/stock/market_report_btn_180320_01.pdf" target="_blank" rel="nofollow">SBI SECURITIES Report [3/20, 2018]</a></li>
          </ul>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Pipelines</h2>
          <p>Updated on 5 11, 2018</p>
          <div style="width:395px; background: white; margin: 0 auto 8px auto">
            <div class="pipeline-arrow-end-legend">Completed</div>
            <div class="pipeline-arrow-prepared-legend">On planning</div>
            <div class="pipeline-arrow-legend">On going</div>
            <div class="pipeline-arrow-sale-legend">Launch</div>
            <div class="pipeline-arrow-plan-legend">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <table border="1" style="table-layout: fixed; overflow-wrap: break-word; width: 1328px; font-size: 0.8em; margin: 0 auto;">
            <colgroup>
              <col span="1" style="width: 140px;">
              <col span="1" style="width: 117px;">
              <col span="1" style="width: 135px;">
              <col span="1" style="width: 110px;">
              <col span="8" style="width: 62px;">
              <col span="1" style="width: 75px;">
              <col span="1" style="width: 255px;">
            </colgroup>
            <thead>
              <tr>
                <th rowspan="2">Project</th>
                <th rowspan="2">Compound<br>(Generic name)</th>
                <th rowspan="2">Indication</th>
                <th rowspan="2">Partnered party</th>
                <th rowspan="2">Discovery</th>
                <th rowspan="2">Pre-Clin,</th>
                <th colspan="3">Clinical Studies</th>
                <th rowspan="2">NDA</th>
                <th rowspan="2">Approval</th>
                <th rowspan="2">Sales</th>
                <th rowspan="2">Territory</th>
                <th rowspan="2">Remarks</th>
              </tr>
              <tr style="font-size: 0.9em;">
                <th>Phase 1</th>
                <th>Phase 2</th>
                <th>Phase 3</th>                    
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="5"><a href="http://stock.ariafloat.com/raqualia/pipeline/tegoprazan.html">PotassiumCompetitive acid blocker<br>(P-CAB)</a></td>
                <td rowspan="5">RQ-00000004<br>(Tegoprazan)<br>CJ-12420 [CJ HealthCare]<br>LXI-15028 [Luoxin Pharma]</td>
                <td>RE/NERD</td>
                <td>-</td>
                <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA<br>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="4">RE/NERD</td>
                <td rowspan="4">CJ HealthCare</td>
                <td colspan="6"><div class="pipeline-arrow">NDA (August 2017)</div></td>
                <td colspan="2"><div class="pipeline-arrow-plan2">Launch<br>2018-2019</div></td>
                <td>Korea</td>
                <td class="text-left pipeline-option">Market Size (Korea): 50 billion yen (500 billion won) *Investigation of RaQualia</td>
              </tr>
              <tr>
                <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option">Re-contracted: CJ HealthCare => Luoxin Pharma<br>Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia</td>
              </tr>
              <tr>
                <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>ROW</td>
                <td class="text-left pipeline-option">ROW: Latin America, East European, Middle East</td>
              </tr>
              <tr>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Taiwan<br>Southeast Asia</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td><a href="http://stock.ariafloat.com/raqualia/pipeline/trpm8-blocker.html">TRPM8 blocker</a></td>
                <td>RQ-00434739</td>
                <td>Neuropathic pain</td>
                <td>-</td>
                <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>P2X7 receptor antagonist</td>
                <td>RQ-00466479<br>AKP-23494954 [Asahi Kasei Pharma]</td>
                <td>Neuropathic pain</td>
                <td>Asahi Kasei Pharma</td>
                <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Global</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="2">Selective sodium channel blocker</td>
                <td>-</td>
                <td>-</td>
                <td>Maruho</td>
                <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Global</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>-</td>
                <td>Pain</td>
                <td>-</td>
                <td><div class="pipeline-arrow3">Discovery</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="2">Ion channel</td>
                <td>On Identity Test</td>
                <td>Pain</td>
                <td>XuanZhu Pharma</td>
                <td><div class="pipeline-arrow3">On going</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>-</td>
                <td>Gastrointestinal</td>
                <td>EA Pharma</td>
                <td><div class="pipeline-arrow3-end">Completed</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>protein-protein interaction inhibitor</td>
                <td>On Identity Test</td>
                <td>Pain</td>
                <td>Interprotein</td>
                <td><div class="pipeline-arrow3">On going</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="4">5-HT4 partial agonist</td>
                <td rowspan="3">RQ-00000010</td>
                <td>Gastroparesis<br>Functional dyspepsia<br>Chronic Constipation</td>
                <td>-</td>
                <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>UK</td>
                <td rowspan="2" class="text-left pipeline-option">Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)</td>
              </tr>
              <tr>
                <td>Gastroparesis<br>Functional dyspepsia<br>?</td>
                <td>ZTE Coming Biotech</td>
                <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
              </tr>
              <tr>
                <td>Gastroparesis</td>
                <td>-</td>
                <td colspan="3"><div class="pipeline-arrow">Investigator Clinical Trial</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center</td>
              </tr>
              <tr>
                <td>RQ-00000009<br>AAT-009 [AskAt]</td>
                <td>Dementia</td>
                <td>AskAt</td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Global</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="2">5-HT2B antagonist</td>
                <td rowspan="2">RQ-00310941</td>
                <td rowspan="2">IBS-D</td>
                <td>-</td>
                <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>UK</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>ZTE Coming Biotech</td>
                <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>Motilin receptor agonist</td>
                <td>RQ-00201894</td>
                <td>Gastroparesis<br>Functional dyspepsia<br>Post - operative Ileus</td>
                <td>-</td>
                <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td rowspan="4">Ghrelin receptor agonist</td>
                <td rowspan="3"><a href="http://stock.ariafloat.com/raqualia/pipeline/ghrelin-receptor-agonist-rq-00000005.html">RQ-00000005<br>（Capromorelin）<br>AT-002 [Aratana]</a></td>
                <td rowspan="2">Weight loss, Anorexia: Dog</td>
                <td rowspan="3">Aratana Therapeutics<br>(Global (Animal))</td>
                <td colspan="8"><div class="pipeline-arrow-sale">Launch (October 2017)</div></td>
                <td>USA</td>
                <td rowspan="3" class="text-left pipeline-option">Product name: Entyce®</td>
              </tr>
              <tr>
                <td colspan="7"><div class="pipeline-arrow-plan">Approval (2018)</div></td>
                <td><div class="pipeline-arrow-plan2">Launch<br>2019</div></td>
                <td>Europe</td>
              </tr>
              <tr>
                <td>Weight loss, Anorexia: Cat</td>
                <td colspan="5"><div class="pipeline-arrow">Long term toxicity test</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
              </tr>
              <tr>
                <td>RQ-00433412</td>
                <td>Anorexia associated with cancer</td>
                <td>-</td>
                <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>Ziprasidone</td>
                <td>RQ-00000003<br>(Ziprasidone Hydrochloride Monohydrate)<br>ME2112 [Meiji Seika Pharma]</td>
                <td>Schizophrenia, Bipolar disorder</td>
                <td>Meiji Seika Pharma</td>
                <td colspan="5"><div class="pipeline-arrow">On going P3</div></td>
                <td><div class="pipeline-arrow-plan2">NDA<br>2019</div></td>
                <td colspan="2"><div class="pipeline-arrow-plan2">Launch<br>2020</div></td>
                <td>Japan</td>
                <td class="text-left pipeline-option">Market Size (Japan): 160 Billion Yen *Investigation of RaQualia</td>
              </tr>
              <tr>
                <td rowspan="9">EP4 antagonist</td>
                <td rowspan="6"><a href="http://stock.ariafloat.com/raqualia/pipeline/ep4-antagonist-rq-00000007.html">RQ-00000007<br>（Grapiprant）<br>AAT-007 [AskAt]<br>AT-001 [Aratana]<br>ARY-007 [Arrys]</a></td>
                <td rowspan="2">Osteoarthritis: Dog</td>
                <td rowspan="2">Aratana Therapeutics<br>(Global (Animal))</td>
                <td colspan="8"><div class="pipeline-arrow-sale">Launch (January 2017)</div></td>
                <td>USA</td>
                <td rowspan="2" class="text-left pipeline-option">Product name: Galliprant®<br>With this product Aratana makes strategic alliance with Elanco</td>
              </tr>
              <tr>
                <td colspan="7"><div class="pipeline-arrow">Approval (January 2018)</div></td>
                <td><div class="pipeline-arrow-plan2">Launch<br>2018</div></td>
                <td>Europe</td>
              </tr>
              <tr>
                <td rowspan="2">Cancer</td>
                <td rowspan="4">AskAt<br>(Global (Excluding animal))</td>
                <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)<br>Development: Arrys affiliate <a href="https://kyntherapeutics.com/" target="_blank" rel="nofollow">Kyn Therapeutics</a></td>
              </tr>
              <tr>
                <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo Tai Kang Medical Technology</td>
              </tr>
              <tr>
                <td rowspan="2">Pain</td>
                <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma</td>
              </tr>
              <tr>
                <td rowspan="3"><a href="http://stock.ariafloat.com/raqualia/pipeline/ep4-antagonist-rq-00000008.html">RQ-00000008<br>AAT-008 [AskAt]<br>AT-019 [Aratana]</a></td>
                <td>Animal</td>
                <td rowspan="3">AskAt<br>(Global)</td>
                <td colspan="5"><div class="pipeline-arrow-plan">Development started (2018)</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Global</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => Aratana</td>
              </tr>
              <tr>
                <td rowspan="2">Cancer</td>
                <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)</td>
              </tr>
              <tr>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo NewBay MedicalTechnology</td>
              </tr>
              <tr>
                <td rowspan="2">COX-2 Inhibitor</td>
                <td rowspan="2">RQ-00317076<br>AAT-076 [AskAt]</td>
                <td rowspan="2">Acute Pain</td>
                <td rowspan="2">AskAt<br>(Global)</td>
                <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma</td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Other Pipelines</h2>
          <p>Updated on 3 3, 2018</p>
          <table border="1" style="table-layout: fixed; overflow-wrap: break-word; width: 540px; font-size: 0.8em; margin: 0 auto;">
            <colgroup>
              <col span="1" style="width: 140px;">
              <col span="1" style="width: 100px;">
              <col span="1" style="width: 100px;">
              <col span="1" style="width: 70px;">
              <col span="1" style="width: 130px;">
            </colgroup>
            <thead>
              <tr>
                <th>Project</th>
                <th>Indication</th>
                <th>Partnered party</th>
                <th>Territory</th>
                <th>Remarks</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>CB2 antagonist</td>
                <td>？</td>
                <td>AskAt</td>
                <td>？</td>
                <td></td>
              </tr>
              <tr>
                <td>Dalbavancin</td>
                <td>MRSA Infections</td>
                <td>-</td>
                <td>Japan</td>
                <td>Product name: Dalvance</td>
              </tr>
              <tr>
                <td>Anidulafungin</td>
                <td>Candida Infections</td>
                <td>-</td>
                <td>Japan</td>
                <td>Product name: Eraxis</td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Other Contracts</h2>
          <p>Updated on 3 3, 2018</p>
          <table border="1" style="table-layout: fixed; overflow-wrap: break-word; width: 730px; font-size: 0.8em; margin: 0 auto;">
            <colgroup>
              <col span="1" style="width: 120px;">
              <col span="1" style="width: 500px;">
              <col span="1" style="width: 110px;">
            </colgroup>
            <thead>
              <tr>
                <th>Contractor</th>
                <th>Contract contents</th>
                <th>Remarks</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Takeda Pharmaceutical</td>
                <td>RaQualia agrees to provide its compound to Takeda for pharmacology studies (4 22, 2016)</td>
                <td><a href="http://www.raqualia.co.jp/topics/4138.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>H. Lundbeck A/S<br>(Denmark)</td>
                <td>RaQualia Grants Patent License to H. Lundbeck</td>
                <td><a href="http://www.raqualia.co.jp/rq-cms/wp-content/uploads/10239957dd48f8d431d806e8be9b1f8e.pdf" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Shire AG<br>(Swiss)</td>
                <td>RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist</td>
                <td><a href="http://www.raqualia.co.jp/press/385.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">University Collaborative Research</h2>
          <p>Updated on 3 3, 2018</p>
          <a href="http://www.riem.nagoya-u.ac.jp/4/rcrc/" target="_blank" rel="nofollow">RaQualia Pharma Industry-Academia Collaborative Research Center</a>
          <br><br>
          <table border="1" style="table-layout: fixed; overflow-wrap: break-word; width: 770px; font-size: 0.8em; margin: 0 auto;">
            <colgroup>
              <col span="1" style="width: 110px;">
              <col span="1" style="width: 250px;">
              <col span="1" style="width: 300px;">
              <col span="1" style="width: 110px;">
            </colgroup>
            <thead>
              <tr>
                <th>University</th>
                <th>Department</th>
                <th>Research theme</th>
                <th>Remarks</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="9">Nagoya University</td>
                <td>Faculty of Genome Dynamics, RIeM</td>
                <td>Exploration of selective blockers targeting DNA Polymerase eta</td>
                <td><a href="http://www.raqualia.co.jp/topics/3229.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Department of Biochemistry, Graduate School of Medicine</td>
                <td>Exploration of selective blockers targeting specific enzymes for treatment of refractory neuroblastoma.</td>
                <td><a href="http://www.raqualia.co.jp/topics/3358.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Department of Pathology and Biological Responses, Graduate School of Medicine</td>
                <td>Exploration of selective blockers targeting connective tissue growth factors (CTGF) for treatment of malignant mesothelioma</td>
                <td><a href="http://www.raqualia.co.jp/topics/3355.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Department of Nephrology, Internal Medicine, Graduate School of Medicine</td>
                <td>Exploration of small molecule compounds inducing the secretion of cytokines and growth factors from adipose-derived stem cells</td>
                <td><a href="http://www.raqualia.co.jp/topics/3501.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Graduate School of Bioagricultural Sciences</td>
                <td>Antibody production by gene transfer method using chicken</td>
                <td></td>
              </tr>
              <tr>
                <td>Department of Cardiovascular Medicine</td>
                <td>Exploration of selective blockers targeting specific proteins for treatment of cardiac failure</td>
                <td><a href="http://www.raqualia.co.jp/topics/3732.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Institute of Transformative Bio-Molecules (ITbM)</td>
                <td>Exploration of small molecule compounds that regulate circadian rhythms</td>
                <td><a href="http://www.raqualia.co.jp/topics/3749.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Department of Environmental Medicine Laboratory Molecular Metabolism Medicine</td>
                <td>Research for a non-alcoholic steatohepatities (NASH) treatment drug</td>
                <td><a href="http://www.raqualia.co.jp/topics/4393.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Graduate School of Medicine, Respiratory Internal Medicine</td>
                <td>Development of novel therapeutic drugs for mutant KRAS lung cancer using cellular senescence</td>
                <td><a href="http://www.raqualia.co.jp/topics/5277.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Tokyo University</td>
                <td>Graduate School of Medicine Continence Medicine course</td>
                <td>Evaluation of novel treatment mechanisms for urological diseases</td>
                <td><a href="http://www.raqualia.co.jp/topics/4319.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
              <tr>
                <td>Gifu Pharmaceutical University</td>
                <td>Biological function analysis course Pharmacological analysis laboratory</td>
                <td>Research on therapeutic drugs for retinal diseases</td>
                <td><a href="http://www.raqualia.co.jp/topics/4292.html" target="_blank" rel="nofollow">Press release</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">TMRC (subsidiary) Pipeline</h2>
          <p>Updated on 3 3, 2018</p>
          <div style="width:395px; background: white; margin: 0 auto 8px auto">
            <div class="pipeline-arrow-end-legend">Completed</div>
            <div class="pipeline-arrow-prepared-legend">On planning</div>
            <div class="pipeline-arrow-legend">On going</div>
            <div class="pipeline-arrow-sale-legend">Launch</div>
            <div class="pipeline-arrow-plan-legend">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <table border="1" style="table-layout: fixed; overflow-wrap: break-word; width: 1328px; font-size: 0.8em; margin: 0 auto;">
            <colgroup>
              <col span="1" style="width: 140px;">
              <col span="1" style="width: 117px;">
              <col span="1" style="width: 135px;">
              <col span="1" style="width: 110px;">
              <col span="8" style="width: 62px;">
              <col span="1" style="width: 75px;">
              <col span="1" style="width: 255px;">
            </colgroup>
            <thead>
              <tr>
                <th rowspan="2">Project</th>
                <th rowspan="2">Compound<br>(Generic name)</th>
                <th rowspan="2">Indication</th>
                <th rowspan="2">Partnered party</th>
                <th rowspan="2">Discovery</th>
                <th rowspan="2">Pre-Clin,</th>
                <th colspan="3">Clinical Studies</th>
                <th rowspan="2">NDA</th>
                <th rowspan="2">Approval</th>
                <th rowspan="2">Sales</th>
                <th rowspan="2">Territory</th>
                <th rowspan="2">Remarks</th>
              </tr>
              <tr style="font-size: 0.9em;">
                <th>Phase 1</th>
                <th>Phase 2</th>
                <th>Phase 3</th>                    
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="6">TM-411</td>
                <td rowspan="3">TM-411<br>(Tamibarotene)<br>SY-1425 [Syros Pharmaceuticals]</td>
                <td>AML<br>(Acute myelogenous leukemia)</td>
                <td rowspan="3">Syros Pharmaceuticals</td>
                <td colspan="4"><div class="pipeline-arrow">On going P2 (Multiple drug combination)</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Combination with azacitidine</td>
              </tr>
              <tr>
                <td>AML &amp; MDS (Myelodysplastic syndrome)</td>
                <td colspan="4"><div class="pipeline-arrow">On going P2 (Multiple drug combination)</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Combination with daratumumab</td>
              </tr>
              <tr>
                <td>Breast cancer<br>(BS)</td>
                <td colspan="4"><div class="pipeline-arrow-prepared">On planning P2</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option">Scheduled to start taking into consideration the effectiveness of AML/MDS combination test</td>
              </tr>
              <tr>
                <td rowspan="3">TM-411<br>(Tamibarotene)</td>
                <td>Neuroblastoma<br>(NB)</td>
                <td>Ohara Pharmaceutical</td>
                <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>Japan</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>Acute promyelocytic leukemia<br>(APL)</td>
                <td>Toko Pharmaceutical Industrial</td>
                <td colspan="6"><div class="pipeline-arrow">NDA</div></td>
                <td></td>
                <td></td>
                <td>China</td>
                <td class="text-left pipeline-option"></td>
              </tr>
              <tr>
                <td>Neutropenia<br>(NP)</td>
                <td>-</td>
                <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td></td>
                <td>USA</td>
                <td class="text-left pipeline-option"></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container" style="max-width: 700px;">
          <p>Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.<br>Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.</p>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container">
          <!-- Google AdSense -->
          <div id="adsense" style="width: 70%; margin: 0px auto; text-align: center;">
            <h6>Advertisements</h6>
            <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
            <!-- ad1 -->
            <ins class="adsbygoogle"
                  style="display:block"
                  data-ad-client="ca-pub-6825342955400774"
                  data-ad-slot="4426216447"
                  data-ad-format="auto"></ins>
            <script>
            (adsbygoogle = window.adsbygoogle || []).push({});
            </script>
          </div>
        </div>
      </section>
    </main>
    <footer class="text-muted" style="background-color: #F2F2F2;">
      <div class="container">
        <p class="float-right">
          <a class="none-a" href="#top">Page top</a>
        </p>
        <p><a class="none-toppage" href="http://stock.ariafloat.com/">&copy; Ariafloat Stock.</a>
        </p>
      </div>
    </footer>
    <script src="../../js/vendor/modernizr-3.5.0.min.js"></script>
    <script src="https://code.jquery.com/jquery-3.2.1.min.js" integrity="sha256-hwg4gsxgFZhOsEEamdOYGBf13FyQuiTwlAQgxVSNgt4=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.3/umd/popper.min.js" integrity="sha384-vFJXuSJphROIrBnz7yo7oB41mKfc8JzQZiCq4NCceLEaO4IHwicKwpJf9c9IpFgh" crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/js/bootstrap.min.js" integrity="sha384-alpBpkh1PFOepccYVYDB4do5UnbKysX5WZXm3XxPqe5iKTfUKjNkCk9SaVuEZflJ" crossorigin="anonymous"></script>
    <script src="../../js/plugins.js"></script>
    <script src="../../js/main.js"></script>
  </body>
</html>
